Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544694 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
A Phase 3 study of Dry Eye Disease, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
- 4
- Study locations
NCT06544694: Completed Phase 3 study of Dry Eye Disease, sponsored by Alcon Research.
NCT06544694 is a Phase 3 study of Dry Eye Disease that has completed, run by Alcon Research. The registered enrollment target is 79 participants, below the 253-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06544694, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
Primary Outcome
Goblet cells are specialized epithelial cells that secrete mucins onto the ocular surface to help hydrate and lubricate the eye surface. Samples of conjunctiva were collected on filter papers based on a technique called impression cytology. The filter papers were then processed in a lab to measure the number of goblet cells (cells/mm2). The percent change in goblet cell density at Day 90 compared to Day 1 (Baseline) was calculated. A positive change value indicates an improvement. Only one eye (
Conditions Studied
Interventions
- DRUG 0.003% AR-15512
- OTHER Artificial Tears
Study Locations (4)
North Carolina
- Oculus Research - Garner
- Wilmington Eye - Leland
- CORE, Inc. - Shelby
Kentucky
- Butchertown Clinical Trials - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 3 |
What the finished NCT06544694 record still lists
NCT06544694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 253-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which 0.003% AR-15512 is the first listed.
NCT06544694 reports a single indexed study location in North Carolina, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06544694 about?
NCT06544694 is a clinical study titled "A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease". The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
What is the current status of trial NCT06544694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2024-10-08. Estimated completion is 2025-03-21.
What conditions does trial NCT06544694 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT06544694?
The interventions under investigation include: 0.003% AR-15512 (DRUG), Artificial Tears (OTHER).
Who is sponsoring clinical trial NCT06544694?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544694 being conducted?
This trial has 4 study locations across Kentucky, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06544694's enrollment target sits among peer trials
79 28th of 33 higher than 6 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
A Study Designed to Evaluate Tear Production
COMPLETED · Phase 3
-
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
COMPLETED · Phase 3
-
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI